Skip to Content

Sunshine Biopharma Inc SBFM

Rating as of

Morningstar’s Analysis

Valuation
Currency in USD
Is it the right time to buy or sell?
Find out with Morningstar Premium
Is it the right time to buy or sell?
Find out with Morningstar Premium

1-Star Price

PREMIUM

5-Star Price

PREMIUM

Economic Moat

PREMIUM

About Quantitative Ratings

Morningstar Quantitative ratings for equities (denoted on this page by) are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies withratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating. Click here for more on how to use these ratings.

Company Profile

Business Description

Sunshine Biopharma Inc is a pharmaceutical company operating in Canada. It focuses on the research, development, and commercialization of proprietary drugs for the treatment of various forms of cancer. The key product of the company is Adva-27a, a small molecule that destroys multidrug resistant cancer cells, including pancreatic cancer cells, small-cell lung cancer cells, breast cancer cells and uterine sarcoma cells. The company also sells several prescription generic drugs under its own brand SBI such as SBI-Anastrozole for treatment of Breast Cancer, SBI-Letrozole for treatment of Breast Cancer, SBI-Bicalutamide for treatment of Prostate Cancer and SBI-Finasteride for treatment of benign prostatic hyperplasia.

Contact
6500 Trans-Canada Highway, 4th Floor
Pointe-Claire, QC, H9R 0A5
T +1 514 426-6161
Sector Healthcare
Industry Drug Manufacturers - Specialty & Generic
Most Recent Earnings Sep 30, 2020
Fiscal Year End Dec 31, 2020
Stock Type Speculative Growth
Employees 3